Showing 1451-1460 of 1614 results for "".
- Aerie Pharmaceuticals Receives European Commission Approval for Glaucoma Treatment Roclandahttps://modernod.com/news/aerie-pharmaceuticals-receives-european-commission-approval-for-glaucoma-treatment-roclanda/2478740/Aerie Pharmaceuticals announced the European Commission (EC) has granted a marketing authorization for Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the reduction of elevated IOP in adult patients with primary open-angle glaucoma or ocular hypertension for whom monoth
- Moderna’s COVID-19 Vaccine Becomes Second to Nab EU Authorizationhttps://modernod.com/news/modernas-covid-19-vaccine-becomes-second-to-nab-eu-authorization/2478725/The European Commission on Wednesday granted a conditional marketing authorization for Moderna’s COVID‑19 vaccine mRNA-1273, making it the second coronavirus vaccine authorized in the EU. The decision comes hours after the European Medicines Agency (EMA) had recommended authorizing mRNA-127
- VisionQuest Biomedical Gains FDA 510(k) Clearance for the Image Quality Analyzer Softwarehttps://modernod.com/news/visionquest-biomedical-gains-fda-510k-clearance-for-the-image-quality-analyzer-software/2478706/VisionQuest Biomedical announced that the company has received 510(k) clearance from the FDA to market the Image Quality Analyzer (IQA) software, which reduces unreadable images captured in teleretinal screening programs by retinal photographers. The IQA is a software system intended for u
- Nicox’s Licensee Bausch + Lomb Secures Approval of Vyzulta in Colombiahttps://modernod.com/news/nicoxs-licensee-bausch-lomb-secures-approval-of-vyzulta-in-colombia/2478694/Nicox announced that its partner, Bausch + Lomb, has received approval for latanoprostene bunod ophthalmic solution, 0.024% (marketed as Vyzulta In the United States) in Colombia, where it will be marketed under the brand name Cliropta. Vyzulta is currently commercialized in the United Sta
- Norlase Announce the Addition of Distributor Partnershipshttps://modernod.com/news/norlase-announce-the-addition-of-distributor-partnerships/2478690/Norlase announced the addition of distributor partnerships in Eastern Europe, Middle East, Oceania and Southeast Asia. “Following our recent expansion into the broader European countries, we are thrilled to establish distributor relationships in these key markets,” Oliver Hvidt, CEO and Pr
- EU Authorizes First COVID-19 Vaccine With Pfizer, BioNTech’s Comirnatyhttps://modernod.com/news/eu-authorizes-first-covid-19-vaccine-with-pfizer-biontechs-comirnaty/2478691/The European Commission on Monday granted a conditional marketing authorization to Pfizer and BioNTech’s coronavirus vaccine BNT162b2, which will go by the name Comirnaty, with the decision coming mere hours after the Committee for Medicinal Products for Human Use (CHMP) gave its backing fo
- The Cassini Ambient Now Compatible With the Catalys Precision Laser Systemhttps://modernod.com/news/the-cassini-ambient-now-compatible-with-the-catalys-precision-laser-system/2478642/Cassini Technologies announced that the compatibility between the latest cOS 6.0 software for the Catalys Precision Laser System and the Cassini Ambient is ready for market launch. The Cassini Ambient and Catalys Precision Laser System will be jointly promoted as part of a collaboration agreement
- Topcon Announces the US Launch of RDx Telehealth Software Platformhttps://modernod.com/news/topcon-announces-the-us-launch-of-rdx-telehealth-software-platform/2478617/Topcon Healthcare announced that it has launched its new Topcon RDx ocular telehealth software platform in the US market. Topcon RDx is an eye health exam platform that allows practitioners to connect to their office remotely and conduct comprehensive eye exams in real-time from virtual
- Aerie Pharmaceuticals Receives Positive CHMP Opinion for Roclanda in the European Unionhttps://modernod.com/news/aerie-pharmaceuticals-receives-positive-chmp-opinion-for-roclanda-in-the-european-union/2478543/Aerie Pharmaceuticals announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of the marketing authorization application (MAA) for Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.0
- Lumenis Launches Digital Duet SLT-YAG Platformhttps://modernod.com/news/lumenis-launches-digital-duet-digital-slt-yag-platform/2478540/Lumenis announced the launch of the Digital Duet SLT-YAG platform. The Digital Duet, which Lumenis describes as the first digital SLT-YAG system on the market, improves glaucoma treatment and posterior capsulotomy with the introduction of advanced digital and connectivity capabilities—rede